“Do I still need this?” sounds like a straightforward medication question, but for many people it’s loaded with fear: fear of relapse, fear of withdrawal, and fear that a clinician will hear the question as mistrust. I’m Dr. Saundra Jain, and today I'll be talking about the human side of deprescribing in psychopharmacology, where the real work often lives at the intersection of evidence and relationship. 

We talk about why the deprescribing conversation so often starts years too late, and how a simple invitation at the time of the first prescription can prevent silence and risk down the road. You’ll hear what patients commonly carry but don’t say out loud: worries about disappointing a prescriber, shame about still needing medication, and uncertainty about what “better” is supposed to look like. I share clinical language that keeps the door open even when the safest answer is “not right now,” so “no” doesn’t get translated as “don’t bring this up again.” 

We also get practical about safe tapering: why “just cutting back” isn’t a plan, how motivational interviewing helps us hold ambivalence without forcing a premature decision, and how shared decision making combines clinical judgment with patient goals and lived experience. I introduce the TAPER framework (Timing, Associations, Perceived risks, Evolution, Resources) to guide a deprescribing conversation that starts with the person, not the pill bottle. 

If this helped you think differently about tapering psychiatric medication, subscribe, share the show with a colleague or friend, and leave a review so more people can find these conversations. What would help you or your patients feel safe enough to ask, “Do I still need this?”

A consent form can be signed in seconds, but the fear that follows a missing conversation can last for weeks or years. We talk about the moment clinicians and patients quietly confuse documentation with informed consent, and why that confusion shows up later as shame, silence, and stopped meds. If you work in mental health care or you take psychiatric medication yourself, this is a grounded look at how trust is built or lost in the small moments. 

We walk through the real-world side effects patients often struggle to say out loud: tremor that turns into a terrifying story about Parkinson’s disease, sexual side effects that hit intimacy and identity, and weight gain that reshapes confidence and relationships. We also reflect on tardive dyskinesia and the devastation of learning, years into treatment, that a risk was never discussed. The takeaway is not “tell patients everything” or “say less so no one worries.” It is learning how to offer context, name what matters, and make room for questions before patients feel forced to manage side effects alone by skipping doses or stopping treatment. 

We bring in motivational interviewing as a practical bridge: asking permission before giving information, checking how much detail is helpful today, and inviting patients into shared decision making. Consent becomes something living and revisitable as people age, priorities shift, new relationships begin, and new evidence emerges. 

A single comment before surgery sticks for decades: “You must be pretty sick.” It was said after noticing an insulin pump, and it reveals a mistake we make all the time in mental health care. We treat certain treatment tools as proof of failure or severity, instead of seeing them as smart choices that can make day to day life easier. From that story, we step into the most misunderstood part of psychopharmacology: the adherence conversation. 

We talk about why missed doses are not automatically “resistance,” why forgetting is human, and why taking medication can feel like waking up to a diagnosis every morning. We also get practical about what helps: empathy before education, and motivational interviewing that starts with permission and curiosity. You’ll hear language you can use right away to explore ambivalence, uncover what an option represents to a patient, and move from persuasion to partnership. 

Then we dig into long acting injectables, including common fears about injections, the stigma attached to “shots,” and why LAIs can be less about control and more about freedom. We explore recovery-oriented care, the ripple effects on families who carry the reminder burden, and why offering evidence-based options earlier, including in first episode psychosis, may prevent relapse and protect a person’s life trajectory. 

If you care about medication adherence, shared decision-making, and reducing stigma in psychiatric treatment, this one will change how you frame choices. What treatment option might you be saving for later that deserves a place in today’s conversation?

The weirdest part of clinical work is that the better your recommendation is, the more stuck a patient can seem. You listen, you assess, you explain the evidence, and then the plan quietly dies: the medication is never started, it is stopped without a word, therapy never happens, and the lifestyle change turns into another “I know, but.” I’m Dr. Saundra Jain, and this conversation is about a skill that helps treatment stick without turning the visit into a tug-of-war.

Motivational interviewing is not a model of psychotherapy. It’s a practical style of communication that helps patients explore their own motivations, work through ambivalence, and move toward behavior change in a way that feels collaborative. We dig into why persuasion often backfires, the “writing reflex” that pulls clinicians into fixing mode, and the science of reactance, how people protect autonomy when they feel pressured or judged. We also reframe “resistance” as something more human: fear, grief, exhaustion, and the conflict of wanting change while also wanting things to stay the same.

You’ll get concrete tools you can use right away in psychopharmacology and beyond, including the OARS framework (open-ended questions, affirmations, reflective listening, summaries), asking permission before offering information, and simple scaling questions that invite change talk. We also name what motivational interviewing cannot do, and how to stay respectful and direct when safety requires it. What’s one conversation this week where you can bring more curiosity and less persuasion?

A medication can be the right choice and still never get taken. That’s not a science problem. It’s a human one, and it’s why we’re starting a conversation about the part of psychopharmacology that rarely shows up in a clinical trial: the lived experience of care.

I’m Dr. Saundra Jain, and I’m launching The Human Side of Psychopharmacology with one guiding belief: every encounter is therapeutic. After decades of work alongside psychiatric prescribers, therapists, patients, and families, I keep coming back to the same question: what helps treatment stick after the appointment ends? We talk about how trust is built, how hope is protected, and how uncertainty can be navigated without losing the person sitting across from us.

Mental health care is moving quickly toward precision medicine, digital tools, biomarkers, AI, and new therapies. I love that progress but I also worry about what gets lost when speed and innovation crowd out connection. The future of psychiatric care is both better treatments and better experiences of treatment, because engagement, shared decision making, and the clinician patient relationship shape adherence and outcomes.

You’ll hear real clinical stories that reveal the hidden gap between the treatment plan and real life: the patient who agrees with the diagnosis but never starts the medication because she’s scared, and the patient who stops an antidepressant in silence due to sexual side effects and embarrassment. If you want practical ways to make it safer for patients to tell the truth, ask the questions they can’t quite say, and keep hope alive when treatment gets hard, you’re in the right place. Subscribe, share this with a colleague, and leave a review so more clinicians can build care that patients actually experience as healing.